INNSBRUCK, Austria--(BUSINESS WIRE)--Austrian biomarker developer BIOCRATES Life Sciences AG (www.biocrates.com) announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc (www.chenomx.com). Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.
